Robert W Shafer

List of Publications by Year
in descending order

91 papers	7,658 citations	87888 38 h-index	56724 83 g-index
96 all docs	96 docs citations	96 times ranked	7050 citing authors

#	Article	IF	Citations
1	Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE, 2009, 4, e4724.	2.5	823
2	The biological and clinical significance of emerging SARS-CoV-2 variants. Nature Reviews Genetics, 2021, 22, 757-773.	16.3	778
3	Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research, 2003, 31, 298-303.	14.5	730
4	Web Resources for HIV Type 1 Genotypic-Resistance Test Interpretation. Clinical Infectious Diseases, 2006, 42, 1608-1618.	5.8	545
5	Rationale and Uses of a Public HIV Drugâ€Resistance Database. Journal of Infectious Diseases, 2006, 194, S51-S58.	4.0	325
6	HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. Aids, 2007, 21, 215-223.	2.2	277
7	Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clinical Microbiology Reviews, 2002, 15, 247-277.	13.6	259
8	HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Reviews, 2008, 10, 67-84.	1.0	218
9	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 565-575.	9.1	217
10	HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution, 2016, 46, 292-307.	2.3	215
11	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. PLoS Medicine, 2015, 12, e1001810.	8.4	188
12	2014 Update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2014, 22, 642-50.	0.1	173
13	HIV-1 Protease Mutations and Protease Inhibitor Cross-Resistance. Antimicrobial Agents and Chemotherapy, 2010, 54, 4253-4261.	3.2	169
14	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Societyâ€"USA Panel. Clinical Infectious Diseases, 2019, 68, 177-187.	5.8	156
15	2017 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine, 2016, 24, 132-133.	0.1	132
16	2019 update of the drug resistance mutations in HIV-1. Topics in Antiviral Medicine, 2019, 27, 111-121.	0.1	127
17	The HIVdb System for HIV-1 Genotypic Resistance Interpretation. Intervirology, 2012, 55, 98-101.	2.8	124
18	2015 Update of the Drug Resistance Mutations in HIV-1. Topics in Antiviral Medicine, 2015, 23, 132-41.	0.1	103

#	Article	IF	Citations
19	A systematic review of the genetic mechanisms of dolutegravir resistance. Journal of Antimicrobial Chemotherapy, 2019, 74, 3135-3149.	3.0	95
20	HIV-1 Subtype B Protease and Reverse Transcriptase Amino Acid Covariation. PLoS Computational Biology, 2007, 3, e87.	3.2	92
21	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. Molecular Biology and Evolution, 2022, 39, .	8.9	84
22	Human immunodeficiency virus type 1 reverse transcriptase and protease mutation search engine for queries. Nature Medicine, 2000, 6, 1290-1292.	30.7	83
23	HIV-1 Protease, Reverse Transcriptase, and Integrase Variation. Journal of Virology, 2016, 90, 6058-6070.	3.4	72
24	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. PLoS ONE, 2015, 10, e0145772.	2.5	72
25	More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1. ELife, 2016, 5, .	6.0	70
26	Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE, 2022, 17, e0261045.	2.5	70
27	SARS-CoV-2 Antiviral Therapy. Clinical Microbiology Reviews, 2021, 34, e0010921.	13.6	64
28	Comparison of an In Vitro Diagnostic Next-Generation Sequencing Assay with Sanger Sequencing for HIV-1 Genotypic Resistance Testing. Journal of Clinical Microbiology, 2018, 56, .	3.9	62
29	Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds. Viruses, 2020, 12, 1006.	3.3	60
30	Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens. PLoS ONE, 2013, 8, e67188.	2.5	59
31	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. Lancet Infectious Diseases, The, 2017, 17, 296-304.	9.1	58
32	Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis. Microbiology Spectrum, 2022, 10, .	3.0	53
33	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000â€“2016: A Pooled Sequence Analysis. EClinicalMedicine, 2019, 9, 26-34.	7.1	51
34	Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance. Journal of Antimicrobial Chemotherapy, 2020, 75, 170-182.	3.0	50
35	Rapid Communication: Efavirenz- and Adefovir Dipivoxilâ€“Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 221-226.	2.1	48
36	Standardized Comparison of the Relative Impacts of HIV-1 Reverse Transcriptase (RT) Mutations on Nucleoside RT Inhibitor Susceptibility. Antimicrobial Agents and Chemotherapy, 2012, 56, 2305-2313.	3.2	48

#	Article	IF	Citations
37	Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population. Clinical Infectious Diseases, 2019, 68, 213-221.	5.8	46
38	Curbing the rise of HIV drug resistance in low-income and middle-income countries: the role of dolutegravir-containing regimens. Lancet Infectious Diseases, The, 2019, 19, e246-e252.	9.1	41
39	Predicting the Response to Combination Antiretroviral Therapy: Retrospective Validation of geno2phenoâ€THEO on a Large Clinical Database. Journal of Infectious Diseases, 2009, 199, 999-1006.	4.0	40
40	Next-Generation Sequencing for HIV Drug Resistance Testing: Laboratory, Clinical, and Implementation Considerations. Viruses, 2020, 12, 617.	3.3	40
41	Predictive Value of HIVâ€1 Genotypic Resistance Test Interpretation Algorithms. Journal of Infectious Diseases, 2009, 200, 453-463.	4.0	39
42	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. Microbiology Spectrum, 2021, 9, e0109621.	3.0	39
43	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. Clinical Infectious Diseases, 2016, 63, 836-843.	5.8	37
44	HIV Type 1 Envelope Subtype C Sequences from Recent Seroconverters in Zimbabwe. AIDS Research and Human Retroviruses, 2000, 16, 973-979.	1.1	35
45	Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C. Viruses, 2010, 2, 2696-2739.	3.3	35
46	Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0158560.	2.5	35
47	HIVâ€1 transmitted drug resistance surveillance: shifting trends in study design and prevalence estimates. Journal of the International AIDS Society, 2020, 23, e25611.	3.0	33
48	A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. Aids, 2014, 28, F1-F8.	2.2	32
49	The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Reviews, 2000, 2, 211-228.	1.0	32
50	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. PLoS ONE, 2017, 12, e0181357.	2.5	31
51	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. EBioMedicine, 2017, 18, 225-235.	6.1	28
52	Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1. Antimicrobial Agents and Chemotherapy, 2013, 57, 4290-4299.	3.2	23
53	Rapid Communication: Efavirenz- and Adefovir Dipivoxilâ€“Based Salvage Therapy in Highly Treatment-Experienced Patients: Clinical and Genotypic Predictors of Virologic Response. Journal of Acquired Immune Deficiency Syndromes (1999), 2000, 23, 221-226.	2.1	22
54	Drug resistance and antiretroviral drug development. Journal of Antimicrobial Chemotherapy, 2005, 55, 817-820.	3.0	21

#	Article	IF	Citations
55	Moderate-to-High Levels of Pretreatment HIV Drug Resistance in KwaZulu-Natal Province, South Africa. AIDS Research and Human Retroviruses, 2019, 35, 129-138.	1.1	21
56	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. PLoS ONE, 2020, 15, e0225352.	2.5	20
57	Similar Prevalence of Low-Abundance Drug-Resistant Variants in Treatment-Naive Patients with Genotype 1a and 1b Hepatitis C Virus Infections as Determined by Ultradeep Pyrosequencing. PLoS ONE, 2014, 9, e105569.	2.5	18
58	Prospective Evaluation of the Vela Diagnostics Next-Generation Sequencing Platform for HIV-1 Genotypic Resistance Testing. Journal of Molecular Diagnostics, 2019, 21, 961-970.	2.8	17
59	Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots. Journal of Clinical Microbiology, 2016, 54, 2597-2601.	3.9	16
60	Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients. Drugs, 2016, 76, 75-98.	10.9	15
61	Genetic Variability of HIV-1 for Drug Resistance Assay Development. Viruses, 2016, 8, 48.	3.3	14
62	Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update. Journal of Infectious Diseases, 2017, 216, S843-S846.	4.0	14
63	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. Journal of Infectious Diseases, 2020, 221, 1962-1972.	4.0	14
64	Public availability of HIV-1 drug resistance sequence and treatment data: a systematic review. Lancet Microbe, The, 2022, 3, e392-e398.	7.3	14
65	Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons. AIDS Research and Human Retroviruses, 2021, 37, 736-743.	1.1	13
66	NucAmino: a nucleotide to amino acid alignment optimized for virus gene sequences. BMC Bioinformatics, 2017, 18, 138.	2.6	12
67	Temporal Trends in HIV-1 Mutations Used for the Surveillance of Transmitted Drug Resistance. Viruses, 2021, 13, 879.	3.3	10
68	Adherence to contemporary antiretroviral treatment regimens and impact on immunological and virologic outcomes in a US healthcare system. PLoS ONE, 2022, 17, e0263742.	2.5	9
69	Multiplex Solid-Phase Melt Curve Analysis for the Point-of-Care Detection of HIV-1 Drug Resistance. Journal of Molecular Diagnostics, 2019, 21, 580-592.	2.8	8
70	Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens. Open Forum Infectious Diseases, 2020, 7, ofaa316.	0.9	8
71	Q148N, a Novel Integrase Inhibitor Resistance Mutation Associated with Low-Level Reduction in Elvitegravir Susceptibility. AIDS Research and Human Retroviruses, 2016, 32, 702-704.	1.1	7
72	Diff-seq: A high throughput sequencing-based mismatch detection assay for DNA variant enrichment and discovery. Nucleic Acids Research, 2018, 46, e42-e42.	14.5	7

#	Article	IF	Citations
73	Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences. Scientific Data, 2018, 5, 180148.	5.3	7
74	Editorial: New Virologic Tools for the Design and Analysis of Clinical Trials. Journal of Infectious Diseases, 1995, 171, 1325-1328.	4.0	6
75	National and International Dimensions of Human Immunodeficiency Virus-1 Sequence Clusters in a Northern California Clinical Cohort. Open Forum Infectious Diseases, 2019, 6, ofz135.	0.9	6
76	Dry Panels Supporting External Quality Assessment Programs for Next Generation Sequencing-Based HIV Drug Resistance Testing. Viruses, 2020, 12, 666.	3.3	6
77	Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by thein silicoapproach. Infection Ecology and Epidemiology, 2018, 8, 1528117.	0.8	5
78	Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. AIDS Research and Therapy, 2020, 17, 64.	1.7	5
79	Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women. EClinicalMedicine, 2020, 22, 100355.	7.1	5
80	Amino Acid Prevalence of HIV-1 pol Mutations by Direct Polymerase Chain Reaction and Single Genome Sequencing. AIDS Research and Human Retroviruses, 2019, 35, 924-929.	1.1	3
81	The Clinical Implications of Pretreatment Drug Resistanceâ€"A Moving Target. Clinical Infectious Diseases, 2019, 69, 215-217.	5.8	3
82	A COMBINED DATA MINING APPROACH FOR INFREQUENT EVENTS: ANALYZING HIV MUTATION CHANGES BASED ON TREATMENT HISTORY. , 2006, , .		3
83	Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations. Pathogens, 2022, 11, 546.	2.8	3
84	Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy. MedGenMed: Medscape General Medicine, 2006, 8, 32.	0.2	1
85	Reply to Ambrosioni et al. Clinical Infectious Diseases, 2019, 68, 1977-1978.	5.8	0
86	P198â€...Dolutegravir rollout and expected prevalence of pretreatment drug resistance to antiretroviral therapy among kenyan women. , 2019, , .		0
87	A SARS-CoV-2 antiviral therapy score card. Global Health & Medicine, 2020, 2, 346-349.	1.4	0
88	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
89	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0
90	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0

#	Article	IF	Citations
91	Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences. , 2020, 15, e0225352.		0